Home
GlaxoSmithKline and Vir Biotechnology Announce EUA from the US FDA for Sotrovimab in Treating Mild-to-Moderate COVID-19

GlaxoSmithKline and Vir Biotechnology Announce EUA from the US FDA for Sotrovimab in Treating Mild-to-Moderate COVID-19

Impacting News May 27, 2021

GlaxoSmithKline and Vir Biotechnology are Granted an EUA for Sotrovimab
GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) announced the U.S. FDA has . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Impacting News
, ,
May 27, 2021

Other Articles